Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma

The FDA has expanded the approved uses of brentuximab (Adcetris) in people with Hodgkin lymphoma. Under the new approval, brentuximab can be used in combination with three other chemotherapy drugs as an initial treatment in patients with advanced disease.

Cancer Currents: An NCI Cancer Research Blog